JP2021534201A5 - - Google Patents

Info

Publication number
JP2021534201A5
JP2021534201A5 JP2021509893A JP2021509893A JP2021534201A5 JP 2021534201 A5 JP2021534201 A5 JP 2021534201A5 JP 2021509893 A JP2021509893 A JP 2021509893A JP 2021509893 A JP2021509893 A JP 2021509893A JP 2021534201 A5 JP2021534201 A5 JP 2021534201A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid sequence
administered
approximately
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509893A
Other languages
English (en)
Japanese (ja)
Other versions
JP7403852B2 (ja
JP2021534201A (ja
Filing date
Publication date
Priority claimed from CN201810948193.1A external-priority patent/CN110846392A/zh
Priority claimed from PCT/CN2018/103937 external-priority patent/WO2020000641A1/zh
Priority claimed from CN201811221305.XA external-priority patent/CN111073899B/zh
Priority claimed from CN201811230856.2A external-priority patent/CN111068071A/zh
Application filed filed Critical
Priority claimed from PCT/CN2019/101538 external-priority patent/WO2020038352A1/en
Publication of JP2021534201A publication Critical patent/JP2021534201A/ja
Publication of JP2021534201A5 publication Critical patent/JP2021534201A5/ja
Priority to JP2023205807A priority Critical patent/JP7690713B2/ja
Publication of JP7403852B2 publication Critical patent/JP7403852B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509893A 2018-08-20 2019-08-20 レーベル遺伝性視神経症を治療するための組成物及び方法 Active JP7403852B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023205807A JP7690713B2 (ja) 2018-08-20 2023-12-06 レーベル遺伝性視神経症を治療するための組成物及び方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
CN201810948193.1A CN110846392A (zh) 2018-08-20 2018-08-20 一种重组腺相关病毒或含其的试剂盒及其应用
CN201810948193.1 2018-08-20
CNPCT/CN2018/103937 2018-09-04
PCT/CN2018/103937 WO2020000641A1 (zh) 2018-06-29 2018-09-04 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
CN201811221305.X 2018-10-19
CN201811221305.XA CN111073899B (zh) 2018-10-19 2018-10-19 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN201811230856.2A CN111068071A (zh) 2018-10-22 2018-10-22 基因治疗Leber遗传学视神经病变
CN201811230856.2 2018-10-22
PCT/CN2018/113799 WO2020082417A1 (zh) 2018-10-22 2018-11-02 基因治疗Leber遗传性视神经病变
CNPCT/CN2018/113799 2018-11-02
CNPCT/CN2018/118662 2018-11-30
PCT/CN2018/118662 WO2020077756A1 (zh) 2018-10-19 2018-11-30 Nd4蛋白的编码序列及其应用
CNPCT/CN2019/070461 2019-01-04
PCT/CN2019/070461 WO2020037938A1 (zh) 2018-08-20 2019-01-04 一种重组腺相关病毒或含其的试剂盒及其应用
PCT/CN2019/101538 WO2020038352A1 (en) 2018-08-20 2019-08-20 Compositions and methods for treating leber's hereditary optic neuropathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023205807A Division JP7690713B2 (ja) 2018-08-20 2023-12-06 レーベル遺伝性視神経症を治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2021534201A JP2021534201A (ja) 2021-12-09
JP2021534201A5 true JP2021534201A5 (cg-RX-API-DMAC7.html) 2022-08-29
JP7403852B2 JP7403852B2 (ja) 2023-12-25

Family

ID=74668040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021509893A Active JP7403852B2 (ja) 2018-08-20 2019-08-20 レーベル遺伝性視神経症を治療するための組成物及び方法
JP2023205807A Active JP7690713B2 (ja) 2018-08-20 2023-12-06 レーベル遺伝性視神経症を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023205807A Active JP7690713B2 (ja) 2018-08-20 2023-12-06 レーベル遺伝性視神経症を治療するための組成物及び方法

Country Status (9)

Country Link
US (2) US11352645B2 (cg-RX-API-DMAC7.html)
EP (1) EP3840785A4 (cg-RX-API-DMAC7.html)
JP (2) JP7403852B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210068014A (cg-RX-API-DMAC7.html)
CN (1) CN112584874A (cg-RX-API-DMAC7.html)
AU (1) AU2019323434A1 (cg-RX-API-DMAC7.html)
CA (1) CA3109432A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101032VA (cg-RX-API-DMAC7.html)
WO (1) WO2020038352A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3814492A4 (en) 2018-06-29 2022-02-23 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
KR20210068014A (ko) 2018-08-20 2021-06-08 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
FI4027983T3 (fi) * 2019-09-11 2026-02-03 Adverum Biotechnologies Inc Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CA3228344A1 (en) * 2021-08-06 2023-02-09 Wuhan Neurophth Biotechnology Limited Company Composition and method for treating leber's hereditary optic neuropathy caused by nd4 mutation
CN116789772A (zh) * 2022-03-18 2023-09-22 北京安龙生物医药有限公司 Aav5扩容衣壳突变体及其扩容检测方法
KR20240109203A (ko) * 2022-12-29 2024-07-10 주식회사 엣진 레베르 유전성 시신경병증의 미토콘드리아 염기 변이 교정 시스템
CN118320132A (zh) * 2024-04-26 2024-07-12 首都医科大学附属北京友谊医院 重组腺相关病毒rAAV2/Rec2作为胰腺靶向性载体的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
WO1997039776A1 (en) 1996-04-19 1997-10-30 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
AU2001250912B2 (en) * 2000-03-21 2007-01-04 Curagen Corporation VEGF-modulated genes and methods employing them
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
ES2932278T3 (es) 2004-06-01 2023-01-17 Genzyme Corp Composiciones y métodos para prevenir la agregación del vector AAV
US20130022979A1 (en) * 2005-04-18 2013-01-24 Genesis Genomics Inc. 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER
ES2541771T3 (es) 2005-05-03 2015-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Expresión de una proteína mitocondrial mediante un enfoque alotópico mejorado
EP2089412A4 (en) * 2006-10-23 2010-01-27 John Guy SUPPRESSION OF OXIDATIVE STRESS OF MITOCHONDRIEN
WO2008101233A2 (en) * 2007-02-16 2008-08-21 University Of Florida Research Foundation Inc. Mitochondrial nucleic acid delivery systems
HRP20140405T1 (hr) * 2007-06-20 2014-06-20 Galapagos N.V. Molekularni ciljevi i metode za identificiranje spojeva za lijeäśenje degenerativnih bolesti kostiju i zglobova
ES2563984T3 (es) * 2008-10-22 2016-03-17 Quark Pharmaceuticals, Inc. Métodos para el tratamiento de trastornos oculares
EP2529020B1 (en) 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
CN102517304B (zh) 2011-12-16 2013-08-28 中国农业科学院生物技术研究所 重组葡萄糖氧化酶的优化基因及其表达载体和应用
US20160289674A1 (en) * 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
CN102634527B (zh) * 2012-04-11 2013-11-06 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
SG11201702116VA (en) * 2014-09-17 2017-04-27 Univ Iowa Res Found Viral rna segments as immunomodulatory agents and vaccine components
CN104450747B (zh) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂
CA2991301A1 (en) * 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CA2973885A1 (en) * 2016-07-21 2018-01-21 Stealth Biotherapeutics Corp Therapeutic compositions including mitochondrial-targeted creatine compounds and uses thereof to treat and prevent mitochondrial diseases and conditions
EP3548039B1 (en) * 2016-12-04 2023-07-19 Alavi Khorassani Moghadam, Marcel Victor Ribavirin for use in the treatment of a mitochondrial disease
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
CN111372598A (zh) * 2017-08-11 2020-07-03 联合生物科技公司 使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况
US20210163898A1 (en) * 2018-04-16 2021-06-03 The Children's Hospital Of Philadelphia Mitochondrial rna import for treating mitochondrial disease
EP3802840A1 (en) * 2018-06-11 2021-04-14 Gensight Biologics SA Recombinant aav vectors and methods of using the same
WO2020000641A1 (zh) 2018-06-29 2020-01-02 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
EP3814492A4 (en) * 2018-06-29 2022-02-23 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
WO2020010491A1 (zh) 2018-07-09 2020-01-16 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN111073899B (zh) 2018-10-19 2021-01-01 武汉纽福斯生物科技有限公司 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN110846392A (zh) 2018-08-20 2020-02-28 武汉纽福斯生物科技有限公司 一种重组腺相关病毒或含其的试剂盒及其应用
CN111068071A (zh) 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
KR20210068014A (ko) 2018-08-20 2021-06-08 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用

Similar Documents

Publication Publication Date Title
Lipworth et al. Effect of ciclesonide and fluticasone on hypothalamicpituitary-adrenal axis function in adults with mild-to-moderate persistent asthma
Kelly Comparison of inhaled corticosteroids
Knutsson et al. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function
KR20010110803A (ko) 약제학적 조성물
JP2024530954A5 (cg-RX-API-DMAC7.html)
JP2024518735A5 (cg-RX-API-DMAC7.html)
Güven Different potent glucocorticoids, different routes of exposure but the same result: iatrogenic Cushing’s syndrome and adrenal insufficiency
WO2014105978A1 (en) Methods of treatment using bevacizumab
US20110144072A1 (en) Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants
Mehdipour et al. Role of corticosteroids in oral lesions
Helfer et al. Corticosteroids and adrenal suppression: characterising and avoiding the problem
JP2024543509A5 (cg-RX-API-DMAC7.html)
JP2022537555A5 (cg-RX-API-DMAC7.html)
JP2024519196A5 (cg-RX-API-DMAC7.html)
JP2022500364A5 (cg-RX-API-DMAC7.html)
IL312515A (en) Bispecific cd16a binders
Ververeli et al. Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma
JP2024540304A5 (cg-RX-API-DMAC7.html)
Vanzieleghem et al. A comparison of budesonide and beclomethasone dipropionate nasal aerosols in ragweed-induced rhinitis
JP2024516886A5 (cg-RX-API-DMAC7.html)
Myers Treatment of multiple sclerosis with ACTH and corticosteroids
JP2024527001A5 (cg-RX-API-DMAC7.html)
IL312514A (en) Corticosteroid reduction in treatment with anti-cd38 antibodies
Shapiro Corticosteroids in the treatment of allergic disease: principles and practice
Smith et al. A controlled trial of beclomethasone dipropionate for asthma